{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:27:54Z","timestamp":1787128074200,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>Osteoporosis weakens bones and increases the risk of fractures. Denosumab is a medication that reduces bone loss and increases bone mineral density (BMD). In this real-world study, we followed patients who received denosumab every 6 months for 10\u00a0years. We found that bone density continued to improve throughout treatment. People who had taken bisphosphonates before starting denosumab responded just as well in the long term. Blood tests showed stable reduction of bone turnover markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Denosumab produces durable BMD gains and low fracture rates in clinical trials, but long-term real-world evidence is limited, especially on the effect of prior bisphosphonate exposure and characteristics of patients who fracture during therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a 10-year single-center real-world retrospective study including patients receiving continuous denosumab 60\u00a0mg every 6 months. Clinical, biochemical, and densitometric data were extracted from an institutional electronic database. Longitudinal changes in BMD at total hip, lumbar spine, and femoral neck were analyzed using linear mixed-effects models adjusted for baseline BMD, age, baseline severe vertebral fractures, and glucocorticoid exposure. Bone turnover markers (CTX, ALP, PTH) were analyzed with mixed-effects models adjusted for renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 145 patients were included (mean age 70.9 years; 95.9% women). Over 10 years, BMD increased significantly at all skeletal sites: +12.9% at the total hip, + 16.3% at the lumbar spine, and +6.0% at the femoral neck. CTX and ALP showed marked and sustained reduction, whereas PTH remained stable over time. Prior bisphosphonate exposure did not modify long-term BMD trajectories at any site, and group differences in CTX converged after treatment initiation. Patients who sustained fractures showed significantly attenuated lumbar spine BMD gains, while hip sites displayed similar trajectories to non-fractured patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-world setting, continuous denosumab therapy for 10 years produced robust and sustained BMD gains, accompanied by a durable and stable reduction in bone turnover. Prior bisphosphonate exposure influenced only early biochemical differences and did not affect decade-long BMD responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01757-y","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:12:34Z","timestamp":1787127154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term effects of denosumab: a 10-year single-center retrospective study"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3965-5295","authenticated-orcid":false,"given":"Federico","family":"Aldegheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5134-1304","authenticated-orcid":false,"given":"Matteo","family":"Appoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Passoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4389-1322","authenticated-orcid":false,"given":"Vittorio","family":"Zibordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9692-2293","authenticated-orcid":false,"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7471-3076","authenticated-orcid":false,"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0755","authenticated-orcid":false,"given":"Giovanni","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1691-2196","authenticated-orcid":false,"given":"Francesco","family":"Pollastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-232X","authenticated-orcid":false,"given":"Angelo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-5655","authenticated-orcid":false,"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"1757_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1137671","volume":"14","author":"G Corrao","year":"2021","unstructured":"Corrao G, Biffi A, Porcu G, Ronco R, Adami G, Alvaro R et al (2021) Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021. Front Endocrinol 14:1137671. https:\/\/doi.org\/10.3389\/fendo.2023.1137671","journal-title":"Front Endocrinol"},{"key":"1757_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002973","volume":"9","author":"G Adami","year":"2023","unstructured":"Adami G, Tsourdi E, Rossini M, Funck-Brentano T, Chapurlat R (2023) Patients with osteoporosis: children of a lesser god. RMD Open 9:e002973. https:\/\/doi.org\/10.1136\/rmdopen-2022-002973","journal-title":"RMD Open"},{"key":"1757_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-025-02991-z","volume":"37","author":"O Lamy","year":"2025","unstructured":"Lamy O, Everts-Graber J, Rodriguez EG (2025) Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach. Aging Clin Exp Res 37:70. https:\/\/doi.org\/10.1007\/s40520-025-02991-z","journal-title":"Aging Clin Exp Res"},{"key":"1757_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221124543","volume":"14","author":"A Fassio","year":"2022","unstructured":"Fassio A, Gatti D, Bertelle D, Fracassi E, Zanetti G, Viapiana O et al (2022) Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data. Ther Adv Musculoskelet Dis 14:1759720X221124543. https:\/\/doi.org\/10.1177\/1759720X221124543","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1757_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221105009","volume":"14","author":"G Adami","year":"2022","unstructured":"Adami G, Gavioli I, Rossini M, Viapiana O, Orsolini G, Benini C et al (2022) Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Ther Adv Musculoskelet Dis 14:1759720X221105009. https:\/\/doi.org\/10.1177\/1759720X221105009","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1757_CR6","doi-asserted-by":"publisher","unstructured":"Adami G, Fassio A, Gatti D, Viapiana O, Benini C, Danila MI, et al (2022) Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. Therapeutic Advances in Musculoskeletal ;14:1759720X221083541. https:\/\/doi.org\/10.1177\/1759720X221083541.","DOI":"10.1177\/1759720X221083541"},{"key":"1757_CR7","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26:2773\u201383. https:\/\/doi.org\/10.1007\/s00198-015-3234-7","journal-title":"Osteoporos Int"},{"key":"1757_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1757_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"1757_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39:58\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"1757_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2023.101437","volume":"27","author":"D Krueger","year":"2023","unstructured":"Krueger D, Tanner SB, Szalat A, Malabanan A, Prout T, Lau A et al (2023) DXA reporting updates: 2023 Official Positions of the International Society for Clinical Densitometry. J Clin Densitom 27:101437. https:\/\/doi.org\/10.1016\/j.jocd.2023.101437","journal-title":"J Clin Densitom"},{"key":"1757_CR12","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/jbmr\/zjaf100","volume":"40","author":"T Vilaca","year":"2025","unstructured":"Vilaca T, Lui L-Y, Schini M, Ewing SK, Thompson A, Vittinghoff E et al (2025) Treatment-related changes in total hip bone mineral density are applicable to trials of varied study designs and to drugs with differing mechanisms of action: meta-regression results from the FNIH-ASBMR SABRE study. J Bone Miner Res 40:1228\u201337. https:\/\/doi.org\/10.1093\/jbmr\/zjaf100","journal-title":"J Bone Miner Res"},{"key":"1757_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.acra.2020.07.028","volume":"28","author":"D Albano","year":"2021","unstructured":"Albano D, Agnollitto PM, Petrini M, Biacca A, Ulivieri FM, Sconfienza LM et al (2021) Operator-related errors and pitfalls in dual energy X-ray absorptiometry: how to recognize and avoid them. Acad Radiol 28:1272\u201386. https:\/\/doi.org\/10.1016\/j.acra.2020.07.028","journal-title":"Acad Radiol"},{"key":"1757_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2026.01.751","author":"X Xiong","year":"2026","unstructured":"Xiong X, Wong CH, Tsoi KH, Loong CHN, Fong CHY, Lee ACH et al (2026) Denosumab therapy beyond 10 years: subsequent treatment and densitometric outcomes. Endocr Pract. https:\/\/doi.org\/10.1016\/j.eprac.2026.01.751","journal-title":"Endocr Pract"},{"key":"1757_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206239","volume":"13","author":"A Catalano","year":"2024","unstructured":"Catalano A, Oliveri C, Natale G, Agostino RM, Squadrito G, Gaudio A et al (2024) Renal function is associated with changes in bone mineral density in postmenopausal osteoporotic women treated with denosumab: data from a retrospective cohort study. J Clin Med 13:6239. https:\/\/doi.org\/10.3390\/jcm13206239","journal-title":"J Clin Med"},{"key":"1757_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","volume":"106","author":"A Broadwell","year":"2021","unstructured":"Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S et al (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106:397\u2013409. https:\/\/doi.org\/10.1210\/clinem\/dgaa851","journal-title":"J Clin Endocrinol Metab"},{"key":"1757_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren \u00d6, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829\u20131835. https:\/\/doi.org\/10.1002\/jbmr.403","journal-title":"J Bone Miner Res"},{"key":"1757_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL et al (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227\u2013235. https:\/\/doi.org\/10.1007\/s00198-012-2052-4","journal-title":"Osteoporos Int"},{"key":"1757_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117407","volume":"193","author":"P Rotman-Pikielny","year":"2025","unstructured":"Rotman-Pikielny P, Barzilai-Yosef L, Ramaty E, Braginski-Shapira S, Meron MK, Lurie TH (2025) Parathyroid hormone levels following denosumab vs. zoledronic acid therapy for osteoporosis. Bone 193:117407. https:\/\/doi.org\/10.1016\/j.bone.2025.117407","journal-title":"Bone"},{"key":"1757_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00198-025-07601-2","volume":"36","author":"JH Lee","year":"2025","unstructured":"Lee JH, Heo S-J, Kim KM, Lee JE (2025) Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumab. Osteoporos Int 36:1661\u20131669. https:\/\/doi.org\/10.1007\/s00198-025-07601-2","journal-title":"Osteoporos Int"},{"key":"1757_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00223-024-01218-z","volume":"115","author":"A Fassio","year":"2024","unstructured":"Fassio A, Andreola S, Gatti D, Pollastri F, Gatti M, Fabbrini P et al (2024) Long-term bone mineral density changes in kidney transplant recipients treated with denosumab: a retrospective study with nonequivalent control group. Calcif Tissue Int 115:23\u201330. https:\/\/doi.org\/10.1007\/s00223-024-01218-z","journal-title":"Calcif Tissue Int"},{"key":"1757_CR22","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/jbmr.1681","volume":"27","author":"D Gatti","year":"2012","unstructured":"Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR et al (2012) Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 27:2259\u201363. https:\/\/doi.org\/10.1002\/jbmr.1681","journal-title":"J Bone Miner Res"},{"key":"1757_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","volume":"30","author":"F Cosman","year":"2024","unstructured":"Cosman F, Langdahl B, Leder BZ (2024) Treatment sequence for osteoporosis. Endocr Pract 30:490\u2013496. https:\/\/doi.org\/10.1016\/j.eprac.2024.01.014","journal-title":"Endocr Pract"},{"key":"1757_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-025-07717-5","volume":"37","author":"S Nayak","year":"2026","unstructured":"Nayak S, Greenspan SL (2026) A systematic review and meta-analysis of sequential treatment strategies for osteoporosis. Osteoporos Int 37:1\u201313. https:\/\/doi.org\/10.1007\/s00198-025-07717-5","journal-title":"Osteoporos Int"},{"key":"1757_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241234584","volume":"16","author":"A Fassio","year":"2024","unstructured":"Fassio A, Gatti D, Biffi A, Ronco R, Porcu G, Adami G et al (2024) The sequential antifracturative treatment: a meta-analysis of randomized clinical trials. Ther Adv Musculoskelet Dis 16:1759720X241234584. https:\/\/doi.org\/10.1177\/1759720X241234584","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1757_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body J-J, Gonzalez Rodriguez E, Anastasilakis AD et al (2021) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106:264\u201381. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"1757_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S et al (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381. https:\/\/doi.org\/10.1359\/jbmr.090716","journal-title":"J Bone Miner Res"},{"key":"1757_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040594","volume":"103","author":"X Jiang","year":"2024","unstructured":"Jiang X, Hou S, Deng X, Hu L, Wang J, Hou D (2024) Sequential treatment from bisphosphonate to denosumab improves lumbar spine bone mineral density in postmenopausal osteoporosis patients: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 103:e40594. https:\/\/doi.org\/10.1097\/MD.0000000000040594","journal-title":"Medicine (Baltimore)"},{"key":"1757_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/CIA.S511622","volume":"20","author":"G Guan","year":"2025","unstructured":"Guan G, Du Y, Tang W, Chen M, Yu W, Li H et al (2025) Impacts of prior anti-osteoporosis treatments on sequential denosumab responses in BMD changes among postmenopausal osteoporosis women in East China: real-world data analysis. CIA 20:573\u2013586. https:\/\/doi.org\/10.2147\/CIA.S511622","journal-title":"CIA"},{"key":"1757_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1993","volume":"7","author":"A Yamamoto","year":"2024","unstructured":"Yamamoto A, Nagao M, Nishizaki Y, Maeda E, Ishijima M (2024) Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: a retrospective single-center cohorts study. Health Sci Rep 7:e1993. https:\/\/doi.org\/10.1002\/hsr2.1993","journal-title":"Health Sci Rep"},{"key":"1757_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bone.2013.11.011","volume":"59","author":"YL Ma","year":"2014","unstructured":"Ma YL, Zeng QQ, Chiang AY, Burr D, Li J, Dobnig H et al (2014) Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone 59:139\u2013147. https:\/\/doi.org\/10.1016\/j.bone.2013.11.011","journal-title":"Bone"},{"key":"1757_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117567","volume":"199","author":"C Bustamante-Gomez","year":"2025","unstructured":"Bustamante-Gomez C, Fu Q, Goellner JJ, Thostenson JD, Reyes-Pardo H, O\u2019Brien CA (2025) Potent suppression of bone remodeling by denosumab does not blunt the anabolic response to romosozumab in mice. Bone 199:117567. https:\/\/doi.org\/10.1016\/j.bone.2025.117567","journal-title":"Bone"},{"key":"1757_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8738959","volume":"2016","author":"A S\u00e1nchez","year":"2016","unstructured":"S\u00e1nchez A, Brun LR, Salerni H, Costanzo PR, Gonz\u00e1lez D, Bagur A et al (2016) Effect of denosumab on bone mineral density and markers of bone turnover among postmenopausal women with osteoporosis. J Osteoporos 2016:1\u20136. https:\/\/doi.org\/10.1155\/2016\/8738959","journal-title":"J Osteoporos"},{"key":"1757_CR34","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.metabol.2015.06.018","volume":"64","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A et al (2015) Denosumab in treatment-na\u00efve and pre-treated with zoledronic acid postmenopausal women with low bone mass: effect on bone mineral density and bone turnover markers. Metabolism 64:1291\u20131297. https:\/\/doi.org\/10.1016\/j.metabol.2015.06.018","journal-title":"Metabolism"},{"key":"1757_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00223-008-9126-5","volume":"82","author":"S Adami","year":"2008","unstructured":"Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, DiMunno O et al (2008) Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 82:341\u20137. https:\/\/doi.org\/10.1007\/s00223-008-9126-5","journal-title":"Calcif Tissue Int"},{"key":"1757_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4081\/reumatismo.2020.1267","volume":"72","author":"G Adami","year":"2020","unstructured":"Adami G, Giollo A, Rossini M, Orsolini G, Benini C, Viapiana O et al (2020) Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life. Reumatismo 72:71\u20134. https:\/\/doi.org\/10.4081\/reumatismo.2020.1267","journal-title":"Reumatismo"},{"key":"1757_CR37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jbmr.1472","volume":"27","author":"M Austin","year":"2012","unstructured":"Austin M, Yang Y-C, Vittinghoff E, Adami S, Boonen S, Bauer DC et al (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 27:687\u2013693. https:\/\/doi.org\/10.1002\/jbmr.1472","journal-title":"J Bone Miner Res"},{"key":"1757_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00198-018-4687-2","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Chines A, Brandi ML, Papapoulos S, Lewiecki EM, Reginster J-Y et al (2019) The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM extension studies. Osteoporos Int 30:71\u201378. https:\/\/doi.org\/10.1007\/s00198-018-4687-2","journal-title":"Osteoporos Int"},{"key":"1757_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.7326\/M15-2937","volume":"165","author":"WD Leslie","year":"2016","unstructured":"Leslie WD, Majumdar SR, Morin SN, Lix LM (2016) Change in bone mineral density is an indicator of treatment-related antifracture effect in routine clinical practice: a registry-based cohort study. Ann Intern Med 165:465\u2013472. https:\/\/doi.org\/10.7326\/M15-2937","journal-title":"Ann Intern Med"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01757-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01757-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01757-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:12:36Z","timestamp":1787127156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01757-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01757-y","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to protocol 1483CESC approved by our local Ethics Committee, in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was collected for each participant.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided consent for publication of anonymized data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O.V. declares advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Eli Lilly, UCB, AbbVie, MSD, and BMS outside the submitted work. M.R. reports advisory board honoraria, consultancy fees and\/or speaker fees from GSK, ItalFarmaco, Theramex, Janssen-Cilag, UCB, outside the submitted work. G. A. has received advisory board honoraria, consultancy fees and\/or speaker fees from Theramex, UCB, Lilly, Galapagos, Fresenius Kabi, Amgen, BMS, Abiogen and Pfizer. D.G. declares advisory board honoraria, consultancy fees, and\/or speaker fees from Accord Health Care, Abiogen, Amgen, Eli Lilly, Mereo, Neopharmed-Gentili, and UCB outside the submitted work. F.A. has received advisory board honoraria, consultancy fees and\/or speaker fees from Boehringer Ingelheim, UCB Pharma, outside the submitted work.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"123"}}